Compare · BSX vs GKOS
BSX vs GKOS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Glaukos Corporation (GKOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and GKOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.85B, about 10.0x GKOS ($7.19B).
- Over the past year, BSX is down 52.5% and GKOS is up 25.3% - GKOS leads by 77.8 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 11 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Glaukos Corporation
- Price
- $47.17-2.40%
- $124.22+1.26%
- Market cap
- $71.85B
- $7.19B
- 1M return
- -12.87%
- -8.91%
- 1Y return
- -52.55%
- +25.26%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 12
- 11
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest GKOS
- Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)
- Director Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)
- Director Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)
- Director Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)
- Director Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)
- Director Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)
- Director Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)
- SEC Form SD filed by Glaukos Corporation
- Director Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)